FACE VALUE AESTHETICS LTD

Executive Summary

Face Value Aesthetics Ltd, a recently incorporated micro entity in the healthcare sector, currently presents high financial risk due to negative net assets and limited liquidity. While compliance with filing requirements is maintained, the company’s early losses and absence of operational scale raise significant concerns regarding its solvency and viability. Further detailed due diligence on business strategy, creditor terms, and funding plans is essential for a comprehensive risk assessment.

FACE VALUE AESTHETICS LTD - Analysis Report

Company Number: 14785890

Analysis Date: 2025-07-20 12:40 UTC

1. Risk Rating: HIGH
   Justification: The company has net current liabilities of £3,927 and shareholders’ funds are negative at £3,927 as of 31 March 2024, indicating insolvency on a balance sheet basis. Cash holdings are very low (£800), suggesting limited liquidity to meet short-term obligations. As a newly incorporated entity (April 2023), it has no trading history or employees, and has reported a retained loss of £3,932 in its first accounting period.

2. Key Concerns:

• Solvency and Liquidity: Negative net current assets and shareholders’ funds combined with minimal cash suggest significant risk that the company cannot meet its liabilities as they fall due.
• Operational Stability: No employees and a loss in the first period with no turnover data available raise questions about the business model’s viability and revenue generation capacity.
• Limited Financial History and Scale: As a micro entity incorporated less than one year ago, there is insufficient historical data to assess trends or operational stability, increasing uncertainty.

3. Positive Indicators:

• Compliance Status: The company is active, with up-to-date filings (accounts and confirmation statement not overdue).
• Clear Control Structure: Ownership and directorship are consolidated under a single individual which may facilitate swift decision-making.
• Industry Classification: Operating in "Other human health activities" and "Specialist medical practice activities" sectors, which could have growth potential if properly capitalised and executed.

4. Due Diligence Notes:

• Verify the company’s business plan and revenue projections to assess the path to profitability and cash flow generation.
• Investigate the nature and terms of the £4,727 creditors due within one year, including any related party transactions or contingent liabilities.
• Confirm if there have been any subsequent capital injections or arrangements to improve liquidity since the balance sheet date.
• Assess the director’s background and capacity to fund or manage the company through early-stage losses.
• Review any contractual commitments or regulatory approvals necessary for the company’s operations in the healthcare sector.